CytoDyn director receives 574,385 stock options

CytoDyn Inc. director Stephen M. Simes received a grant of 574,385 non-qualified stock options to buy common stock at $0.28 per share.

Rhea-AI Filing Summary

CytoDyn Inc. director Stephen M. Simes received a grant of 574,385 non-qualified stock options to buy common stock at $0.28 per share. The award was approved on March 20, 2026 as his regular annual grant under CytoDyn’s 2012 Equity Incentive Plan.

The options expire on March 20, 2036 and vest in 12 approximately equal monthly installments from April 2026 through March 2027, contingent on his continued service. Following this grant, Simes holds 574,385 derivative securities representing the right to acquire the same number of common shares.

Insider Trade Summary

Grant/Award: 574,385 shares

Grant/Award 1 txn

Insider SIMES STEPHEN M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-qualified stock option (right to buy)	574,385	$0.00	$0.00

Holdings After Transaction: Non-qualified stock option (right to buy) — 574,385 contracts (Direct)

Footnotes (2)

1. F1. This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan").
2. F2. The stock option will vest in 12 approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2026 through March 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CytoDyn (CYDY) report for Stephen M. Simes?

CytoDyn reported that director Stephen M. Simes received a grant of 574,385 non-qualified stock options. The options give him the right to buy CytoDyn common shares at $0.28 each as part of his regular annual equity compensation.

What are the key terms of Stephen M. Simes’ CytoDyn stock option grant?

The grant covers 574,385 non-qualified stock options with an exercise price of $0.28 per share. The options expire on March 20, 2036 and were issued under CytoDyn’s 2012 Equity Incentive Plan as the annual award for fiscal year 2026.

How do Stephen M. Simes’ CytoDyn options vest over time?

The options vest in 12 approximately equal monthly installments beginning in April 2026 and continuing through March 2027. Vesting requires continuous service as defined in CytoDyn’s 2012 Equity Incentive Plan, meaning he earns the options gradually over that one-year period.

Did CytoDyn’s director pay anything for the new stock options?

The options were granted at no upfront cost, with a reported grant price of $0.00 per option. However, Stephen M. Simes must pay $0.28 per share to exercise each option if he chooses to convert them into CytoDyn common stock in the future.

How many CytoDyn derivative securities does Stephen M. Simes hold after this grant?

After the transaction, Stephen M. Simes is reported as holding 574,385 derivative securities. These derivatives are stock options that, if fully vested and exercised, entitle him to buy the same number of CytoDyn common shares at the $0.28 exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/24/2026 - 05:23 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SIMES STEPHEN M

(Last) (First) (Middle)

1111 MAIN STREET, SUITE 660

(Street)

VANCOUVER WASHINGTON 98660

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CytoDyn Inc. [ CYDY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-qualified stock option (right to buy)	$0.28	03/20/2026		A		574,385(1)		(2)	03/20/2036	Common Stock	574,385	$0	574,385	D

Explanation of Responses:

1. This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan").

2. The stock option will vest in 12 approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2026 through March 2027.

	/s/ Tyler Blok, Attorney-in-Fact for Stephen M Simes	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)